[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"antibody-typhoid-vaccine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:antibody-typhoid-vaccine":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":18,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":5},"100586905","long-term-protection-of-vi-antibodies-induced-by-bio-tcv-in-indonesian-population-compared-to-pqed-tcv-100586905",false,"NCT06921460","Long-Term Protection of Vi Antibodies Induced by Bio TCV in Indonesian Population Compared to PQed TCV","Long-Term Protection of Vi Antibodies Induced by Vi-DT Conjugate Vaccines (Bio TCV) in Indonesian Population Compared to PQed TCV","Inclusion Criteria:\n\n* Healthy\n* Subject\u002FParents\u002Flegal guardian(s) have been informed properly regarding the study and signed the informed consent form\u002Fand informed assent form.\n* Subject\u002Fparents\u002Flegal guardian(s) will commit to comply with the instructions of the investigator and the schedule of the trial.\n\nExclusion Criteria:\n\n* History of uncontrolled coagulopathy or blood disorders contraindicating for phlebotomy.",true,"ALL","6 Months","60 Years",{"count":21,"type":22},624,"ESTIMATED","OBSERVATIONAL","Typhoid fever is a serious systemic infection caused by the enteric pathogen Salmonella enterica serovar typhi. S typhi is spread by the fecal-oral route. Although largely an endemic disease, S. typhi has epidemic potential. This research aims to determine the long-term immune response after administration of one dose of Bio TCV and PQed TCV vaccines in the population in Indonesia. Research participants will be taken from research participants who complete the Bio TCV (Typhoid 0319) Phase III clinical trial research included in the Main Study Group I.",[26],"Antibody Typhoid Vaccine","NOT_YET_RECRUITING","2025-06-02",{"date":30,"type":31},"2025-06-03","ACTUAL",{"date":33,"type":22},"2025-06-15",{"date":35,"type":22},"2025-12-31",{"name":37,"class":38},"PT Bio Farma","INDUSTRY"]